about
The use of psychotropic medication during pregnancy: how about the newborn?Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderPharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approachPharmacological and toxicological effects of lithium in zebrafish.Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects.Perinatal stress, brain inflammation and risk of autism-review and proposal.Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance.Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms.Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes.Are Attributes of Pregnancy and the Delivery Room Experience Related to Development of Autism? A Review of the Perinatal and Labor Risk Factors and Autism.Prenatal exposure to carbamazepine reduces hippocampal and cortical neuronal cell population in new-born and young mice without detectable effects on learning and memory.Effects of maternal psychotropic drug dosage on birth outcomes.Psychotropic Medication and Substance Use during Pregnancy by Women with Severe Mental Illness.Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium.Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.A pharmacological approach to panic disorder during pregnancy.Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women.Prescribing of psychiatric medication to bereaved parents following perinatal/neonatal death: an observational study.Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases.
P2860
Q24625025-10BF96CC-3B63-459B-B27D-C3F354049398Q24626017-995FCC48-0334-4A9C-971D-BE9A5A6E3FAEQ26774013-AC8F643A-7259-4951-B0AC-5F8524F36F36Q33777992-B1C3DF52-6E54-4BED-ACFE-02B7090A93DBQ33801507-53473E12-A051-428C-AA7C-43E4E6EA99C7Q34285045-EF27382D-6342-4973-B230-30EF15247209Q34467757-10A3A78A-133A-4C74-8E0F-B19C6361859DQ34483257-3501DD35-48FD-49CD-A501-ABB3982E933DQ35238506-CD80D6FA-F197-4F7B-BC14-3CAEA02BAEB8Q36979990-AA1810FB-4DB4-413F-BCC3-133347160DFFQ37309361-8A47CE98-68EE-46B0-A835-27F5A82F9FC8Q37397151-3D3EC23B-AC05-4B92-8FDD-B992C7BD81A4Q37647623-5BACF675-3579-4B2D-B152-658E7EA43299Q38076126-AEC4EF67-1DEC-45F9-8CE5-6DF2F7404708Q38241431-EC8E4585-5662-4BBE-916A-AF53D7F0DD10Q38305749-7230DC84-7444-4EEE-B567-36E1BF0B7D55Q38516009-55B2DE5C-6D83-4950-9CE6-51BC842E6303Q47743073-89AC84FC-6F5E-4A46-91B8-722A805CA6BCQ47822959-65BBE1A1-E9F7-47D7-ADF2-58B393B5C609Q48197725-F70C96E1-C7AF-4F5E-9F65-17F5356DD1B9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug treatment for mood disorders in pregnancy.
@en
Drug treatment for mood disorders in pregnancy.
@nl
type
label
Drug treatment for mood disorders in pregnancy.
@en
Drug treatment for mood disorders in pregnancy.
@nl
prefLabel
Drug treatment for mood disorders in pregnancy.
@en
Drug treatment for mood disorders in pregnancy.
@nl
P1476
Drug treatment for mood disorders in pregnancy.
@en
P356
10.1097/YCO.0B013E3283413451
P577
2011-01-01T00:00:00Z